



Australian Quality Standards and Targets

Therapeutic Colposcopists

| | |
|-------------------|---|
| Standard 1 | <ul style="list-style-type: none"> All treatments must be recorded with type of treatment in accordance with the nomenclature provided in the 2016 Guidelines and include nature of anaesthesia. |
| Standard 2 | <ul style="list-style-type: none"> All participants having local ablative/destructive treatment must have had a cervical biopsy prior to treatment (100%) |
| Standard 3 | <ul style="list-style-type: none"> Of all excisional biopsies taken, more than 90% should be suitable for quality histological examination. |
| Standard 4 | <ul style="list-style-type: none"> There should be histological evidence of HSIL (biopsy or excisional specimen) in >80% of treated cases. |
| Standard 5 | <ul style="list-style-type: none"> The number of participants who are treated under local anaesthesia should be maximised. |
| Standard 6 | <ul style="list-style-type: none"> The proportion of confirmed high grade histological abnormalities should not exceed 5% within 15 months of treatment. |
| Standard 7 | <ul style="list-style-type: none"> Follow up of participants who are treated for high grade histologic abnormality should be maximised, with at least 90% seen within 15 months of treatment. |